Skip to main content
Premium Trial:

Request an Annual Quote

WuXi NextCode Raises $75 Million in Series B Financing

NEW YORK (GenomeWeb) - WuXi NextCode said today that it has closed a $75 million Series B financing in which several of the company's existing investors and partners participated.

Temasek and Yunfeng Capital co-led the financing. Other investors include Amgen Ventures and 3W Partners. Temasek is a Singapore-based investment firm, while Yunfeng is a private equity firm founded by Alibaba Group Holding's Jack Ma.

The new funds will help WuXi advance and commercialize genomic tests for the Chinese market, as well as to strengthen its position in informatics, and expand its capabilities in artificial intelligence and deep learning.

The company has already launched a whole-genome sequencing product for healthy individuals, called HealthCode, in China. The firm presented the first results from a pilot study on HealthCode involving 190 customers at the American College of Medical Genetics and Genomics annual meeting this past March.

The Scan

Polygenic Risk Score to Predict Preeclampsia, Gestational Hypertension in Pregnant Women

Researchers in Nature Medicine provide new mechanistic insights into the development of hypertensive disorders of pregnancy, which may help develop therapeutics.

New Oral Nanomedicine Strategy Targets Gut-Brain Axis to Treat IBD

A new paper in Science Advances describes a platform to design polyphenol-armored oral medicines that are effective at treating inflammatory bowel disease.

Phylogenetic Data Enables New Floristic Map

Researchers in Nature Communications use angiosperm phylogenetic data to refine the floristic regions of the world.

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.